Consumer protection · from the 250-topic plan
The refill cliff: what to do when your GLP-1 program wobbles, stalls, or disappears
Programs fail sideways before they fail forward — shipping slips, support goes quiet, the pharmacy name changes mid-order — and patients standing on a refill cliff have more protections and more runway than panic suggests. The playbook: read the early warnings (this file lists seven); know your clock — the half-life math gives semaglutide (~7-day) and tirzepatide (~5-day) users a genuine grace window, and the reorder-early rule beats it entirely; exercise your records right immediately — HIPAA obligates release within 30 days, and a transfer packet is your bridge; bridge deliberately — a fast new intake at a verified program, or a brand-lane stopgap, beats gray-market improvisation every time; and protect the money — the chargeback ladder and cancellation law cover prepaid months a dying program can't deliver. Calm, sequenced, and mostly paperwork — the whole cliff, mapped below.
Seven early warnings
The pattern-recognition list, from this market's boom-bust archaeology: (1) shipping windows stretching without explanation; (2) support that answers sales questions but not clinical ones; (3) an unannounced pharmacy switch on your label — provenance is the product, so silent substitution is a shout; (4) promo intensity spiking (deep discounts are sometimes cash-flow flares); (5) policy pages quietly rewritten — refunds narrowing, cancellation friction rising; (6) clinician turnover you can feel (every message answered by someone new); (7) the forums lighting up with the same four complaints. One flag is weather; three is a forecast — start the playbook at three.
Your actual clock — longer than panic thinks
The pharmacology is on your side. With half-lives near seven days (semaglutide) and five (tirzepatide), a missed week is a wobble, not a cliff — the missed-dose file maps the take-or-skip windows — and appetite's return is gradual across weeks, not a switch. The planning translation: the reorder-early rule — request refills with 10–14 days of runway, not 2 — converts nearly every program failure from emergency to inconvenience; and if a gap does land, the response is the holds logic (protect habits, protein, structure) rather than panic-buying from whoever ships fastest. Longer gaps have a known cost — re-titration after extended time off — which is a prescriber conversation at the new program, priced into the bridge decision below.
The records move — do it first, not last
The moment warnings stack, send the records request: under HIPAA you're entitled to your chart — intake, prescriptions, dose history, labs — within 30 days, and the leaving file includes the exact ask. Why first: a transfer packet is what lets a new prescriber continue your dose instead of restarting your titration, it's easiest to get while the program still has staff, and it costs nothing to hold. Screenshot your current plan terms and dose page the same day — a dying program's website is evidence with a half-life of its own.
Bridging without the gray market
Two clean bridges. The verified-program bridge: a fast intake at a program passing the five-check screen — the audited anchor's published flow runs same-day-to-days, and the intake conversation should open with your transfer packet and the sentence “continuing at [dose], not restarting” confirmed in writing; the cost index prices every legitimate door. The brand bridge: for some, a month of Zepbound vials ($349 entry) or covered brand therapy spans the gap with the approved product while the new compounded arrangement settles. What never bridges anything: unverifiable “research peptide” sellers and social-media sourcing — the cliff's predators, covered at field-manual strength in the red-flags file; a two-week gap is recoverable, a counterfeit vial may not be.
Protecting the money
Prepaid months a program can't deliver aren't donations. The sequence: written cancellation per the terms you screenshotted (the refund taxonomy tells you what you're owed); then the chargeback ladder — services-not-rendered disputes have strong footing when shipments stop; then, for autoship abuses, the ROSCA-and-state-law stack that survived the click-to-cancel vacatur. File dates matter (card networks run dispute windows), which is one more reason the playbook starts at warning three, not at silence. A program built to answer ↗
FAQ
What should I do if my GLP-1 provider shuts down?
Request your records immediately (owed within 30 days), screenshot your plan terms, bridge via a verified program continuing your dose — transfer packet in hand — and dispute undelivered prepaid months through cancellation, chargeback, and autoship-law channels.
How long can I safely go between doses if refills stall?
Half-lives of ~5–7 days give a genuine grace window — a missed week is manageable per the missed-dose rules — and reordering with 10–14 days of runway prevents most cliffs entirely.
Will a new provider restart my titration?
Not if you arrive with records: a transfer packet lets the new prescriber continue your current dose — confirm “continuing, not restarting” in writing before the first charge.
Can I get money back for undelivered prepaid months?
Often — written cancellation per captured terms, then services-not-rendered chargebacks, then state autoship law; dispute windows reward acting early.
Sources
- HIPAA records-access rules; card-network dispute frameworks; ROSCA and state auto-renewal statutes.
- Half-life and missed-dose pharmacology — companion files.
- Program-failure patterns from the shortage-era market record.